Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application
Pleura and Peritoneum · 2016
DOI: 10.1515/pp-2016-0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pleura and Peritoneum, 2016. Verfasst von Marc Reymond und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Ruhr-University Bochum, Herne, Germany. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a drug delivery technique with superior pharmacological properties for treating peritoneal metastasis (PM). Adding electrostatic loading ( e PIPAC) as an adjunct to aerosol and artificial hydrostatic pressure improved tissue uptake in a preclinical model.
Methods
We report the first e PIPAC use in 3 patients with PM of hepatobiliary-pancreatic (HBP) origin. All 3 patients received concomitant palliative systemic chemotherapy that was discontinued in two patients. PIPAC with cisplatin 7.5 mg/m 2 and doxorubicin 1.5 mg/m 2 was applied intraperitoneally at a pressure of 12 mmHg and a temperature of 37% °C for 30 min. Additionally, a voltage 7,500–9,500 V and a current≤10 µA were applied over a stainless steel brush electrode emitting a stream of electrons. Results : e PIPAC was technically feasible. No intraoperative complication was noted. The procedures were well tolerated with no adverse event CTCAE > 2. Patient 1 with PM of unknown origin (CUP with HBP phenotype) showed an objective histological and radiological response and survived 11 months. Patient 2 with ductal pancreatic cancer underwent secondary resection after ePIPAC with no residual PM; however, tumor recurred 5 months later. Patient 3 with adenocarcinoma of the gallbladder showed a radiological regression of liver infiltration and is alive after 22 months without histological evidence of PM. Conclusion : ePIPAC is technically feasible, is well tolerated and can induce tumor regression of PM in HBP cancers with and without concomitant systemic chemotherapy. These preliminary results justify prospective clinical studies with ePIPAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Ruhr-University Bochum, Herne, Germany.
- Medical School Hanover, Institute of Pathology, Hannover, Germany.
- Department of Radiology, Ruhr-University Bochum, Herne, Germany.
- Department of Gynecology and Obstetrics, Ruhr-University Bochum, Herne, Germany.
Zitieren
APA
Reymond, M., Demtroeder, C., Solass, W., Winnekendonk, G., & Tempfer, C. (2016). Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application. Pleura and Peritoneum. https://doi.org/10.1515/pp-2016-0005
Vancouver
Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C. Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application. Pleura and Peritoneum. 2016. doi:10.1515/pp-2016-0005
BibTeX
@article{Reymond2016,
author = {Reymond, Marc and Demtroeder, Cedric and Solass, Wiebke and Winnekendonk, Guido and Tempfer, Clemens},
title = {Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application},
journal = {Pleura and Peritoneum},
year = {2016},
doi = {10.1515/pp-2016-0005}
}
EUVIMED